Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa

Main selection criteria:

- Age ≥18 years to ≤75 years at the time of ICF signature.

- Diagnosis of non-syndromic RP defined as:

- Clinical diagnosis of non-syndromic RP based on history, mid-peripheral visual
dysfunction, and fundoscopic appearance.

- Diagnosis of non-syndromic RP is confirmed on full-field ERG

- Visual acuity:

- Visual acuity in the dose-escalation cohorts of no better LP.

- Visual acuity in the extension cohort of no better than CF pending review of
dose-escalation cohort data by the DSMB.

- Relatively preserved ganglion cell layer volume and retinal nerve fiber layer
thickness, as measured with spectral domain optical coherence tomography (SD-OCT).

- Interpupillary distance of ≥51 mm and ≤72 mm.

- Refractive error of the study eye between -6 diopters and +6 diopters.

Main non-selection criteria

- Prior receipt of any gene therapy.

- Subjects who have undergone significant ocular surgery (per investigator
determination) within 3 months prior to Visit 1.

- Presence of narrow iridocorneal angles contraindicating pupillary dilation.

- Presence of disorders of the ocular media which interfere with visual acuity and other
ocular assessments, including SD-OCT, during the study period.

- Presence of any systemic or ocular diseases, or pathologies, other than non-syndromic
RP, or their associated therapies, that can cause or have the potential to cause
vision loss.

- Prior vitrectomy or vitreomacular surgery.

- Presence of vitreo-macular adhesion or traction, epiretinal membrane, macular pucker
and macular hole, evident by ophthalmoscopy and/or by SD-OCT examinations and assessed
by the investigator to significantly affect central vision.

- Current evidence of retinal detachment assessed by the investigator to significantly
affect central vision.

- Active ocular inflammation or recurrent history of idiopathic or autoimmune associated
uveitis.

- Presence of an Active Implantable Medical Device.

- Subjects who have undergone thermal laser procedure to the retina within 3 months of
trial entry, or any prior thermal laser procedure to the macular region.